Key Highlights
- Amazon One Medical introduced a comprehensive GLP-1 weight management service integrating virtual consultations, prescriptions, and pharmacy delivery.
- Insurance-covered plans begin at $25 monthly; uninsured injectable treatments like Wegovy and Zepbound are priced from $299 per month.
- The e-commerce giant aims to bring same-day medication delivery to 4,500 urban areas by late 2026.
- Hims & Hers (HIMS) shares plummeted up to 6% during pre-market hours after Amazon’s announcement.
- Bank of America analysts forecast Amazon’s entry could slash HIMS’s GLP-1 business by 31%.
Amazon is diving headfirst into the lucrative obesity treatment sector. The tech giant announced Tuesday it’s launching a comprehensive GLP-1 management service via Amazon One Medical, its healthcare division, merging weight loss treatment with prescription fulfillment and telehealth appointments.
The newly launched service provides patients with branded weight loss medications from Novo Nordisk (Wegovy) and Eli Lilly (Zepbound). For those with insurance coverage, oral GLP-1 medications are available for as little as $25 monthly. Self-paying customers face costs of $149 per month for oral alternatives, while injectable treatments such as Wegovy and Zepbound carry a $299 monthly minimum.
While these rates align with existing market pricing, Amazon’s competitive advantage lies in accessibility — leveraging its powerful distribution infrastructure for same-day fulfillment alongside an integrated patient experience from initial screening through ongoing prescription management.
Tanvi Patel, who leads Amazon Pharmacy as VP and GM, emphasized the initiative aims to improve patient adherence by ensuring medications “are delivered reliably directly to patients.”
Currently available nationwide, the program treats weight management as an ongoing chronic health issue rather than a short-term intervention. It encompasses preliminary health screenings, organized medical consultations, subsequent check-ins, and clinically validated treatment frameworks.
Patients can request prescription renewals on demand, with messaging consultations priced at $29 and video appointments at $49. Amazon’s roadmap includes extending same-day delivery capabilities to 4,500 metropolitan areas before 2026 concludes.
HIMS Takes the Hit
The news dealt a significant blow to Hims & Hers Health. HIMS shares plunged as much as 6% during pre-market activity, though the decline moderated as trading progressed. The market reaction underscores mounting anxiety about Amazon’s encroachment into the affordable GLP-1 segment where HIMS has established its foothold.
The announcement comes at an awkward moment for HIMS. The telehealth company recently pivoted toward branded obesity medications — the premium market segment — precisely when Amazon debuts its competing integrated offering. Bank of America analysts caution this competitive threat could cut HIMS’s GLP-1 revenue stream by 31%.
Additional companies connected to the obesity pharmaceutical sector experienced Tuesday declines, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN).
Amazon’s Expanding GLP-1 Footprint
Tuesday’s rollout represents Amazon’s latest advancement in the GLP-1 arena. Earlier in January, the company introduced same-day shipping for Novo Nordisk’s Wegovy obesity medication. By April, it had incorporated same-day fulfillment for Eli Lilly’s recently approved weight-loss tablet, Foundayo, via its digital pharmacy platform.
The current launch consolidates these separate initiatives into a unified ecosystem — combining primary healthcare, pharmaceutical services, and virtual consultations within a cohesive framework.
Wall Street maintains a Strong Buy rating on AMZN with consensus from 45 analysts — including 42 Buy recommendations and 3 Hold ratings. The consensus price target of $286.74 suggests approximately 13% potential upside from present trading levels.
AMZN shares advanced roughly 1% in trading following the program announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
